Innospera Pharma Appoints Dr. Glenn Crater as Chief Medical Officer to Support Advancement of ING-006 Toward the Clinic
Article content
MONTREAL — Innospera Pharma Inc. ('Innospera'), a private, near-clinical-stage biotechnology company advancing differentiated small molecule modulators of GPR84 and GPR40 to treat inflammatory and metabolic diseases, today announced the appointment of Dr. Glenn Crater, MD, FCCP as Chief Medical Officer (CMO). Glenn will start immediately as a fractional CMO, with the commitment to joining full time as the Company's lead compound reaches the clinic.
Article content
Dr. Crater brings to Innospera over 25 years of clinical, regulatory, and leadership experience in pulmonary medicine and drug development. A board-certified pulmonologist, Dr. Crater has played pivotal roles in advancing respiratory drug candidates, with particular expertise in Idiopathic Pulmonary Fibrosis (IPF) — the initial target indication for Innospera's lead compound, ING-006, which is poised to enter clinical development in the near future.
Article content
'We are thrilled to welcome Glenn to Innospera at this critical moment in our growth,' said François Ravenelle, PhD, Chief Executive Officer of Innospera. 'Having worked closely with Glenn at Inversago Pharma, I've witnessed first-hand his commitment to scientific rigor, clinical excellence, and patient impact. His deep understanding of IPF and drug development will be invaluable as we initiate clinical studies for ING-006 and build a pipeline of novel GPR84/GPR40 modulators.'
Article content
Prior to joining Innospera, Dr. Crater served as Chief Medical Officer at multiple biotechnology companies and held senior medical leadership positions across both private and public firms, contributing to successful regulatory submissions and clinical programs in respiratory and fibrotic diseases.
Article content
'I'm excited to reunite with François and the team at Innospera,' said Dr. Crater. 'ING-006 represents a promising new approach to modulating inflammation and fibrosis via GPCR lipid signaling. I look forward to advancing this program in the clinic and working to deliver transformative therapies for patients living with IPF and related diseases.'
Article content
About Innospera Pharma
Article content
Article content
Article content
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
24 minutes ago
- Globe and Mail
Vaccine stocks muted as investors assess Kennedy's overhaul of key panel
Shares of global vaccine makers were mixed on Tuesday, as investors assessed U.S. Health Secretary Robert F. Kennedy Jr.'s surprising decision to fire all 17 members of a key expert panel late on Monday. Shares of U.S. vaccine maker Moderna (MRNA-Q) fell 2 per cent while Novavax (NVAX-Q) was down marginally. Merck (MRX-N) and Pfizer (PFE-N) rose between 1.4 per cent and 2 per cent. European shares of AstraZeneca (AZN-Q) closed slightly higher, while BioNTech (BNTX-Q) closed marginally lower. Analysts and investors said that while the unprecedented dismissals of all members of the Advisory Committee on Immunization Practices (ACIP) represented a risk for vaccine makers, the weak performance of those stocks in 2025 suggested that Kennedy's skepticism around vaccines was already factored in. Shares of most big drugmakers are down in 2025, compared with a 2-per-cent gain in the S&P 500 index. Since his appointment as health secretary under President Donald Trump, Kennedy has made several changes to reshape the regulation of vaccines, food and medicine. However, firing members of the ACIP remains his most far-reaching move yet. 'For vaccine makers, policy risk has already been cemented into share prices,' Morningstar analyst Karen Anderson said, even though the move was sudden and went against the promises that Kennedy made to Senator Bill Cassidy before his appointment was confirmed. Mr. Kennedy's decision comes less than three weeks before the next panel meeting, where the committee is slated to discuss recommendations for who should receive vaccines for diseases like respiratory syncytial virus, or RSV. 'It seems difficult to refill the panel with experts before the June 25th meeting,' said Jeff Jonas, portfolio manager at Gabelli Funds. 'But it's clearly going to be more difficult and more expensive to get future vaccines approved, and I'd expect to see less industry focus and effort here,' Jonas added, despite recent positive news such as the limited approval of Novavax's COVID shot and Merck's RSV therapy. Some analysts expressed concerns that the new committee members, who have not been named, might be more sympathetic to Mr. Kennedy's views on vaccines, an idea shared by scientific experts and doctors. Although the makeup of a reconstituted ACIP is yet to be determined, 'new members will likely be sympathetic to at least some of RFK's beliefs regarding alleged dangers of vaccines,' Leerink analyst Daina Graybosch wrote in a note. Ms. Graybosch said that the move could negatively impact approved vaccine recommendations and increase the burden of evidence and costs for future vaccine development. It is unclear when Mr. Kennedy will announce the new members, who the agency said are under consideration, or whether the agenda will follow the meeting description posted on the Federal Register on Monday. Be smart with your money. Get the latest investing insights delivered right to your inbox three times a week, with the Globe Investor newsletter. Sign up today.


CBC
26 minutes ago
- CBC
N.S. government prepares engagement table on gender-based violence
A new engagement group on gender-based violence is intended to bring together subject matter experts, people with lived experience and front-line workers as the Nova Scotia government seeks progress on an issue the legislature declared an epidemic last year. Justice Minister Becky Druhan, who is leading the work, said the approach is based on a similar engagement group used to focus on child care when she was education minister. "It has proven to be a very effective way to ensure that sector and community has real, significant and meaningful input into government work," she said in an interview. Druhan said applications will open soon for up to 25 spots. The group's terms of reference and priorities will be finalized soon and then made public. The minister expects the first meeting to happen in the fall and for subsequent meetings at least once every three months. Bringing together insights and knowledge Although the government appreciates the work the sector is doing, Druhan said officials have also heard feedback that there needs to be a way to "knit together the insights and understanding and knowledge of first voices, of families and survivors and those who work on the front line" with the work the government is doing or planning. During the last meeting of the legislature's standing committee on health, the Liberals put forward a motion to create such a roundtable. A vote had been scheduled for Wednesday's committee meeting. In a news release, the party welcomed Druhan's announcement. "When we listen to the people doing this difficult work every day, and to those directly impacted, we can create better policies that save lives," Liberal MLA Iain Rankin said in the release. "I want to thank the presenters who supported the motion last month. Their insights helped build momentum for this important step. I'm hopeful that this initiative leads to real, coordinated action that helps those who need it most." Despite the Liberal motion, Druhan said the idea of an engagement table was something government officials had previously discussed with people connected to the sector. Must lead to change NDP Leader Claudia Chender said in a statement that the new group would only be successful if it leads to change. "We know what the problems are — and we know what must be done. The recommendations from the Mass Casualty Commission, the Lionel Desmond inquiry, and the Final Report of the National Inquiry into Missing and Murdered Indigenous Women and Girls — all provide us with a path forward. Now we need to do the work." For Chender, stable core funding for organizations that work to address and prevent gender-based violence would be a good first step. After tabling its budget earlier this year, the Progressive Conservatives announced additional funding for transition houses amid concerns there was not enough money being directed at the issue. That new money came after seven women were killed in Nova Scotia in less than five months whose deaths were connected to their male partners.


CTV News
43 minutes ago
- CTV News
N.S. reforms for people with disabilities behind schedule but has momentum: province
Vicky Levack, who lives with cerebral palsy, smiles as she adjusts to her new living accommodation in Halifax on Wednesday, Nov. 16, 2022. THE CANADIAN PRESS/Andrew Vaughan HALIFAX — The Nova Scotia government says its five-year plan to bring about sweeping reforms in housing and care for people with disabilities is behind schedule but gaining momentum. In October 2021, the Nova Scotia Court of Appeal ruled that the province was systemically discriminating against people with disabilities. The government was subsequently ordered to make reforms, including to move people out of large institutions and into small homes in the community where they can live independently. However, in a progress report released today the province says only 189 people have left large institutions, a number that is about two-thirds of the goal the government had set for the spring. Scott Armstrong, the minister of social development, says there were delays in finding staff to oversee the transfers to community living, but adds that hiring programs are catching up. The department also says it has succeeded in reducing a wait-list for disabilities services by 293 people, exceeding the plan's original targets. The Disability Rights Coalition — the advocacy group that led the original court case — says the premier's office should be more directly involved in keeping the plan on track. This report by The Canadian Press was first published June 10, 2025. The Canadian Press